Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. ENLV was recently a guest on Biedex Markets’s All-Access.
Enlivex is a clinical-stage biotechnology company focused on macrophage reprogramming that intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis and other indications.
The company’s therapy, AllocetraTM, is being tested as a cure for sepsis, one of the biggest unmet needs in healthcare. Sepsis is the third leading cause of death in hospitals today.
Watch the full interview here:
Featured photo by Pawel Czerwinski on Unsplash.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Biedex Markets.com. Biedex Markets does not provide investment advice. All rights reserved.